APYX Fundamental Analysis - APYX MEDICAL CORP

Fundamental Rating

APYX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. APYX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, APYX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year APYX has reported negative net income.

In the past year APYX has reported a negative cash flow from operations.

In the past 5 years APYX always reported negative net income.

In the past 5 years APYX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -25.35%, APYX perfoms like the industry average, outperforming 46.81% of the companies in the same industry.

Looking at the Return On Equity, with a value of -248.63%, APYX is doing worse than 73.94% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-25.35%
ROE	-248.63%
ROIC	N/A

ROA(3y)-34.86%

ROA(5y)-28.54%

ROE(3y)-98.96%

ROE(5y)-68.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 62.65%, APYX is doing good in the industry, outperforming 63.83% of the companies in the same industry.

APYX's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for APYX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	62.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.12%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for APYX has been increased compared to 1 year ago.

The number of shares outstanding for APYX has been increased compared to 5 years ago.

The debt/assets ratio for APYX is higher compared to a year ago.

2.2 Solvency

APYX has an Altman-Z score of 0.86. This is a bad value and indicates that APYX is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of 0.86, APYX perfoms like the industry average, outperforming 50.53% of the companies in the same industry.

APYX has a Debt/Equity ratio of 5.92. This is a high value indicating a heavy dependency on external financing.

APYX has a Debt to Equity ratio of 5.92. This is amonst the worse of the industry: APYX underperforms 86.70% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	5.92
Debt/FCF	N/A
Altman-Z	0.86

ROIC/WACCN/A

WACC9.11%

2.3 Liquidity

APYX has a Current Ratio of 4.44. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 4.44, APYX is in the better half of the industry, outperforming 75.00% of the companies in the same industry.

APYX has a Quick Ratio of 3.61. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.

APYX has a better Quick ratio (3.61) than 73.94% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.44
Quick Ratio	3.61

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.63% over the past year.

Looking at the last year, APYX shows a decrease in Revenue. The Revenue has decreased by -1.32% in the last year.

APYX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.24% yearly.

EPS 1Y (TTM)56.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.29%

Revenue 1Y (TTM)-1.32%

Revenue growth 3Y-0.29%

Revenue growth 5Y11.24%

Sales Q2Q%12.1%

3.2 Future

The Earnings Per Share is expected to grow by 18.24% on average over the next years. This is quite good.

APYX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.40% yearly.

EPS Next Y44.05%

EPS Next 2Y16.81%

EPS Next 3Y13.43%

EPS Next 5Y18.24%

Revenue Next Year5.75%

Revenue Next 2Y5.36%

Revenue Next 3Y5.8%

Revenue Next 5Y41.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APYX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APYX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

APYX's earnings are expected to grow with 13.43% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.81%

EPS Next 3Y13.43%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for APYX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

APYX MEDICAL CORP

NASDAQ:APYX (12/4/2025, 8:04:33 PM)

After market: 3.95 -0.08 (-1.99%)

4.03

+0.03 (+0.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-06 2025-11-06/bmo

Earnings (Next)03-11 2026-03-11/amc

Inst Owners42.84%

Inst Owner Change-1.14%

Ins Owners14.55%

Ins Owner Change0%

Market Cap165.27M

Revenue(TTM)47.90M

Net Income(TTM)-14.54M

Analysts78

Price Target5.78 (43.42%)

Short Float %0.79%

Short Ratio1.99

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)28.82%

Min EPS beat(2)5.46%

Max EPS beat(2)52.18%

EPS beat(4)4

Avg EPS beat(4)25.6%

Min EPS beat(4)5.46%

Max EPS beat(4)52.18%

EPS beat(8)6

Avg EPS beat(8)9.91%

EPS beat(12)7

Avg EPS beat(12)1.81%

EPS beat(16)9

Avg EPS beat(16)3.5%

Revenue beat(2)1

Avg Revenue beat(2)0.25%

Min Revenue beat(2)-4.69%

Max Revenue beat(2)5.19%

Revenue beat(4)2

Avg Revenue beat(4)0.78%

Min Revenue beat(4)-4.69%

Max Revenue beat(4)5.19%

Revenue beat(8)4

Avg Revenue beat(8)0.71%

Revenue beat(12)5

Avg Revenue beat(12)-1.66%

Revenue beat(16)7

Avg Revenue beat(16)-1.7%

PT rev (1m)41.67%

PT rev (3m)41.67%

EPS NQ rev (1m)-15.15%

EPS NQ rev (3m)-11.75%

EPS NY rev (1m)0%

EPS NY rev (3m)0.68%

Revenue NQ rev (1m)1.74%

Revenue NQ rev (3m)1.79%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.45
P/FCF	N/A
P/OCF	N/A
P/B	28.26
P/tB	28.26
EV/EBITDA	N/A

EPS(TTM)-0.36

EYN/A

EPS(NY)-0.43

Fwd EYN/A

FCF(TTM)-0.23

FCFYN/A

OCF(TTM)-0.21

OCFYN/A

SpS1.17

BVpS0.14

TBVpS0.14

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-25.35%
ROE	-248.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	62.65%
FCFM	N/A

ROA(3y)-34.86%

ROA(5y)-28.54%

ROE(3y)-98.96%

ROE(5y)-68.76%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.12%

GM growth 5Y-2.02%

F-Score4

Asset Turnover0.84

Health

		Industry Rank	Sector Rank
Debt/Equity	5.92
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	188.19%
Cap/Sales	2.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.44
Quick Ratio	3.61
Altman-Z	0.86

F-Score4

WACC9.11%

ROIC/WACCN/A

Cap/Depr(3y)103.68%

Cap/Depr(5y)91.24%

Cap/Sales(3y)1.6%

Cap/Sales(5y)1.67%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)56.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.29%

EPS Next Y44.05%

EPS Next 2Y16.81%

EPS Next 3Y13.43%

EPS Next 5Y18.24%

Revenue 1Y (TTM)-1.32%

Revenue growth 3Y-0.29%

Revenue growth 5Y11.24%

Sales Q2Q%12.1%

Revenue Next Year5.75%

Revenue Next 2Y5.36%

Revenue Next 3Y5.8%

Revenue Next 5Y41.4%

EBIT growth 1Y55.94%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year68.7%

EBIT Next 3Y19.61%

EBIT Next 5Y28.09%

FCF growth 1Y-16.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-11.07%

OCF growth 3YN/A

OCF growth 5YN/A

APYX MEDICAL CORP / APYX FAQ

Can you provide the ChartMill fundamental rating for APYX MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to APYX.

Can you provide the valuation status for APYX MEDICAL CORP?

ChartMill assigns a valuation rating of 0 / 10 to APYX MEDICAL CORP (APYX). This can be considered as Overvalued.

What is the profitability of APYX stock?

APYX MEDICAL CORP (APYX) has a profitability rating of 1 / 10.

APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

APYX MEDICAL CORP / APYX FAQ

Can you provide the ChartMill fundamental rating for APYX MEDICAL CORP?

Can you provide the valuation status for APYX MEDICAL CORP?

What is the profitability of APYX stock?